About this event

  • Date and time Mon 4 Mar 2019 from 9:00am to 5:00pm
  • Location Royal Society of Medicine
  • Organised by Pathology

This meeting covers several main areas of emerging clinical and scientific progress in the area of stem cell transplantation.

Diseases areas that will be covered include: multiple sclerosis, scleroderma, and haematological malignancies. Presentations on major recent clinical and scientific breakthroughs from clinicians, experts, scientific researchers and world leaders in the field. 

Presentations from patients, NHS England, and NICE will provide insight into the experience of living with the disease, public health perspectives on cost and treatment access.

Topics include:

  • Clinical perspectives on new developments in stem cell transplantation therapies and how it impacts patient management 
  • A biomedical research perspective on emerging topics in cellular transplant therapies and remaining challenges 
  • Patient perspectives on living with MS, scleroderma, haematological malignancies 
  • Regulatory/government body perspectives (NHS/NICE/MP) on how emerging cellular transplantation therapies may be regulated and accessed by patients

Tickets

Standard pricing available until 03 March 2019.

Member

RSM Fellow RSM Retired Fellow RSM Associate RSM Trainee RSM Student
£96.00 £75.00 £75.00 £75.00 £39.00

Non - Member

Consultant / GP Trainee AHP / Nurse / Midwife Student
£160.00 £125.00 £125.00 £65.00

Key speakers

Richard Burt

Professor Richard Burt

Chief of Immunotherapy and Autoimmune Diseases in the Department of Medicine at Northwestern Feinberg School of Medicine in Chicago, Illinois, USA

Speaker's biography

Professor Burt's Department, the Division of Immunotherapy and Autoimmune Diseases (DIAD) is the only centre in the world devoted to a unique area of treatment and research utilizing stem cell transplantation in clinical trials for autoimmune diseases and vascular diseases. DIAD pioneered and performed America’s first hematopoietic stem cell transplants to treat: Multiple Sclerosis (MS), Diabetes, Lupus, Crohn’s, Rheumatoid Arthritis, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Phemphigus, Dermatomyositis, Devic’s, Myasthenia Gravis, Polymositis and Scleroderma.

His lecture titled “An update on the MIST (Multiple sclerosis International Stem cell Transplantation) trial” will provide information on the aims and the outcomes of the first and only trial of its kind testing haematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis. As an investigator involved in the trial, Professor Burt can provide unique insights into what this trial means for the future of MS treatment. While the first part of the study demonstrated that this type of stem cell transplantation can be delivered with acceptable safety, the longer-term evaluation is still underway until 2021 and thus an update on the MIST trial will be of great interest to an international audience. Professor Burt will also participate in the panel discussion titled “Should stem cell transplantation be the first-line treatment for multiple sclerosis.” 

Agenda

View the programme

Registration, tea and coffee
Welcome and introduction

Dr Amit Patel, President, Pathology Section, Royal Society of Medicine

Session one

Living with MS, MS Society

Patient

How does haematopoietic stem cell transplantation work for MS?

Professor Paolo Muraro, Imperial College London, UK

Clinical experience the evidence of autologous stem cell transplantation for MS

Professor Richard Burt, Northwestern University, USA

Tea and coffee break
Living with systemic sclerosis, Scleroderma & Raynauds UK
How does haematopoietic stem cell transplantation work for scleroderma?

Dr. Voon Ong, University College London

Clinical experience the evidence of autologous stem cell transplantation for systemic sclerosis and other autoimmune diseases

Professor Richard Burt

Access to autologous stem cell transplantation for autoimmune diseases in the NHS

Professor John Snowden, University of Sheffield

Panel debate: Should autologous stem cell transplantation be first line treatment for MS and systemic sclerosis?

All speakers

Lunch

Session two

Immune effector cell therapy: CAR-T therapy for blood and solid cancer

Living with blood cancer
Evidence for CAR-T cell therapy to treat blood cancers

Dr Amit Patel, University of Liverpool, UK

Clinical experience of immune effector cell therapy for cancer in the NHS

Professor Karl Peggs, University College London, UK

Tea and coffee break
Advances in immune effector cell therapies for cancer

Dr. Martin Pule, University College London, UK

Late post CAR-T cell therapy monitoring and management

Professor Karl Peggs, University College London, UK

Access to CAR-T cell therapy in the NHS for leukaemia and lymphoma

Professor John Snowden, University of Sheffield

Panel debate: what is the role of CAR-T cell therapy and what should be the patient pathway for blood and solid cancers?

All speakers

Closing remarks

Dr Amit Patel

Close of meeting

Evaluation surveys and certificates will be sent by email

Student and trainee question and answers session

All speakers

Close of meeting student and trainee session

Location

Royal Society of Medicine, 1 Wimpole Street, London, W1G 0AE, United Kingdom

Other events of interest

DNM04 Promo
CPD

Spotlight on whistleblowing

This meeting will bring together policy-makers, researchers, clinicians and other healthcare professionals to understand the climate for whistleblowers within the NHS.

  • Price £12 - £60
  • Location Royal Society of Medicine, 1 Wimpole Street, London, W1G 0AE, United Kingdom
Book Book
TEM03 Promo

Medical apps: Mainstreaming innovation

This event on medical apps will examine the growing role that apps are playing in healthcare delivery.

  • Price £24 - £175
  • Location Royal Society of Medicine, 1 Wimpole Street, London, W1G 0AE, United Kingdom
Book Book
OCM03 Hero
CPD

Young women with breast cancer and Sylvia Lawler prize meeting

The latest updates on the scientific, clinical, and psychosocial aspects of breast cancer in young woman and the multi-disciplinary management of these cases.

  • Price £21 - £85
  • Location Royal Society of Medicine, 1 Wimpole Street, London, W1G 0AE, United Kingdom
Book Book